A rare malignancy in the post-transplant period: Myeloma cast nephropathy

Isabel Mesquita¹, Helena Viana¹, Marília Possante¹, Cristina João², Susana Carvalho², Cecília Silva¹, Inês Aires¹, Aníbal Ferreira¹, Francisco Remédio¹, Fernanda Carvalho¹, Fernando Nolasco¹

¹ Hospital Curry Cabral do CHLC, Serviço de Nefrologia e Transplantação, Lisboa, PT
² Instituto Português de Oncologia, Serviço de Hematologia, Lisboa, PT

Received for publication: Feb 27, 2016
Accepted in revised form: Aug 29, 2016

CASE REPORT

ABSTRACT

Myeloma-associated renal disorders are rare events among renal transplants and can occur as recurrent or de novo disease. We describe an unusual case of renal allograft dysfunction due to myeloma cast nephropathy occurring 19 years after having received a renal transplant in a patient with no prior history of multiple myeloma or monoclonal gammopathy preceding transplantation. Our patient was treated with five cycles of chemotherapy (bortezomib, melphalan and steroids), which resulted in short-term improvement in allograft dysfunction and complete haematological remission. The longer patient and graft survival after renal transplantation make post-transplant lymphoproliferative disease more frequent. Multiple myeloma after kidney transplant is rare and an elevated index of suspicion is necessary to make a timely diagnosis of this serious disease. Further work is needed to identify the best treatment options for these patients.

Key-Words: Kidney transplantation; myeloma cast nephropathy; post-transplant lymphoproliferative disease.

INTRODUCTION

Kidney transplantation has experienced dramatic developments over the years, in the treatment and is now the standard treatment for patients with end-stage renal disease¹.

An increased incidence of neoplasm in transplant recipients was first recognized in the 1970s as a serious complication². With longer graft survival and older donors (as well as recipients) and with the introduction of more potent immunosuppressive medication, cancers complicating organ allograft are a major cause of morbidity and mortality after renal transplantation²,³.

In published studies, the incidence of cancer in renal transplant recipients ranges from 2.3-31%³,⁴. Of these, post-transplant lymphoproliferative disease (PTLD) is a serious complication of solid organ transplantation, with an increased risk compared to both the general population and patients on transplant waiting lists⁵,⁶.

Factors predisposing to this increased risk of malignancy include impaired immune surveillance due to use of high-dose immunosuppressive drugs; primary infection or recrudescence of viral infections, such as Epstein-Barr virus, Herpes virus and hepatitis C virus (HCV), and older age⁵,⁷,⁹.

In the United States, approximately around 1% of all cancers and 10% of haematological malignancies in the general population are due to multiple myeloma¹⁰,¹¹. However, despite the frequency of multiple
myeloma, there is limited experience with multiple myeloma in renal transplantation\textsuperscript{11}.

Myeloma-associated kidney disorders occur as recurrent disease, and rarely \textit{de novo} in kidney transplant recipients\textsuperscript{11,12}. These kidney disorders usually manifest with worsening allograft function and proteinuria\textsuperscript{13}. Little is known about the course and outcome of patients who develop multiple myeloma after kidney transplantation. In the first published cases\textsuperscript{7,13-15} the outcome was poor because the therapeutic regimen with alkylator-based therapy used in an immunosuppressed population often resulted in severe infection and death. We believe that this scenario is now quite different with the advent of new myeloma therapies and with the use of less aggressive immunosuppressive protocols.

We report the case of one patient who developed multiple myeloma 19 years after having received a renal transplant.

\section*{CASE REPORT}

A 51-year-old Caucasian female with an autosomal dominant polycystic kidney disease was transplanted with a deceased allograft kidney in 1993. Her past medical history was significant for hypertension and HCV. There was no clinical evidence of multiple myeloma at that time. There were four HLA mismatches (A, B and DR). The surgical procedure was uneventful and immunosuppression (ISS) consisted of prednisolone, cyclosporine and azathioprine. The optimal plasma creatinine after transplantation was 1.0 mg/dl and the patient was diagnosed at discharge with new onset diabetes after transplantation.

In the first two years after transplantation patient experienced cytomegalovirus infection, treated with ganciclovir, and several \textit{Escherichia coli} urinary tract infections (UTI). In the third year post-transplantation, renal function declined to a plasma creatinine 1.5 mg/dl. An allograft biopsy was made at this point and showed interstitial fibrosis and tubular atrophy and arteriolar hyaline thickening, suggesting calcineurin inhibitor toxicity. The cyclosporine dose was reduced. In the fifth year after transplantation, azathioprine was switched to mycophenolate mofetil.

At 7th year post-transplantation the patient was diagnosed with vesicoureteral reflux into the transplanted kidney during investigation of underlying causes of recurrent UTI. She was treated by endoscopic subureteral collagen injection.

Nine years after transplantation she started erythropoiesis-stimulating agents (ESA) to achieve normochromic normocytic anaemia control (darbepoetin alfa 20 mcg, biweekly). In the thirteenth year after transplantation, cyclosporine was switched to tacrolimus as cyclosporine-related minor side effects were observed.

Over the next few years, follow-up visits in the transplant clinic were unremarkable except for several UTI and an increase in ESA dose (from 20 to 80 mcg, weekly), to correct anaemia. The allograft function remained stable (Scr 1.3 mg/dl).

At the follow-up visit during the 19th year post-transplant the patient presented with asthenia and fatigue at minimal efforts. At the time her ISS consisted of tacrolimus (1.5 mg/day) and mycophenolate mofetil (750 mg/day). Mild graft dysfunction was present with a slight creatinine increase (from 1.4 to 1.9 mg/dl). Laboratory work-up revealed haemoglobin of 11 g/dl, total leukocyte count of 5800/mm\textsuperscript{3} and a normal differential count. Serum albumin was 3.6 g/dl, serum calcium 9.2 mg/dl, phosphorus 5.8 mg/dl and alkaline phosphatase 73 U/L. Serum protein electrophoresis revealed the presence of de novo M band and urinary Bence Jones proteins were positive. Serum immunoelectrophoresis showed immunoglobulin A (IgA) lambda monoclonal gammopathy of 1819 mg/dL and presence of urine protein electrophoresis was positive for an abnormal lambda monoclonal band.

An allograft kidney biopsy was performed due to mild creatinine increase and IgA lambda gammopathy. The optical microscopy revealed normal glomeruli and vessels. The majority of proximal tubules were normal. The more profound cortical and the medullar region presented interstitial fibrosis, with mild mononuclear cells infiltrates and tubular atrophy with polymorphic, dense and fragmented tubular casts. One tubular cast was involved by a multinucleated giant cell (Figure 1). The immunofluorescence, performed in frozen fragment, was only positive to immunoglobulin lambda light chain in tubular casts (Figure 2). The Congo Red coloration was negative. Lambda cast nephropathy was the final histological diagnosis.

Subsequent bone marrow showed 30% mature and immature plasma cells, confirming the diagnosis of myeloma. Skeletal survey revealed one osteolytic
lesion in the skull. The patient was referred to haematology and started 5 weekly cycles of chemotherapy. Each cycle consisted of 4 days of bortezomib (1.3 mg/m² daily), 4 days of melphalan (9 ml/m² daily) and 4 days of oral dexamethasone (40 mg daily). She received a total of 5 cycles of chemotherapy, resulting in a complete haematological remission represented by normal IgA lambda levels, negative immunofixation and recovery of baseline graft function. During chemotherapy, she developed leuakopaenia and mycophenolate mofetil was withdrawn, maintaining tacrolimus monotherapy.

The patient continued to be followed-up at the haematology and transplant clinic, with monitoring of immunoelectrophoresis and free light chain.

Five months after the last treatment, tacrolimus was switched to everolimus. This caused proteinuria worsening which led to everolimus suspension and tacrolimus re-introduction.

Eighteen months after last chemotherapy cycle she remains in complete haematological remission with a stable kidney function and serum creatinine level sustained at 1.3 mg/dL.

Her current immunosuppression consists of tacrolimus and mycophenolate mofetil.

Presently, she is 74 years old, 21 years after kidney transplantation and remains in complete haematological remission with stable allograft function.

**DISCUSSION**

PTLD are well-known complication after renal transplantation and occur more frequently in situations where an aggressive immunosuppressive protocol has been used. In PTLP spectrum, patients with malignant lymphomas/multiple myeloma are older, develop the lesions after a longer time interval after transplantation\(^1\), have a higher stage of disease at presentation\(^8\), and lower probability of response to implemented therapeutic strategies\(^8\).

Myeloma-associated kidney disorders have been reported with diverse clinical and histological manifestations in solid organ transplant recipients\(^15,19\). This entity usually occurs as recurrent disease, and rarely de novo in kidney transplant recipients. The risk of developing de novo myeloma after renal transplantation is 4.4 times higher than in the general population; however, this accounts for only 1.3% of all malignancies over a period exceeding 25 years, per the ANZDATA report\(^8,20\).

It is possible that in some cases a previous undetected monoclonal gammopathy of undetermined significance (MGUS), preexisting prior to transplantation, could evolve into manifest myeloma post-transplant as a result of the immunosuppressive regimen. In cases of known and treated myeloma, the disease could recur despite achieving successful remission prior to transplantation\(^15\).
Presence of monoclonal or oligoclonal gammopathies is, however, not infrequent after transplantation. Incidence of benign gammopathies after transplantation varies between 10-30%. Post-transplant MGUS is often transient, usually associated with intense immunosuppression, and the amount of M protein is usually small, and it may have multiple bands.

Light chains (LCs) are removed from the circulation by the kidney. Filtered LCs are reabsorbed by proximal tubule epithelial cells via receptor-mediated endocytosis via the tandem endocytic receptors megalin/cubilin. Excessive endocytosis of LCs triggers activation of nuclear factor jB, which in turn promotes cytokine and chemokine expression leading to tubulointerstitial fibrosis and scarring.

The potential precipitants for myeloma cast nephropathy in post-transplant patients include calcineurin inhibitor toxicity, prolonged cold ischaemia time, transient hypovolaemia, and sudden exposure of the allograft to a high load of filtered free monoclonal light chains.

Although kappa LCs are more commonly reported, there are few cases reporting lambda LC involvement in a renal allograft. It is not known if these pathological differences have significance in clinical outcome and allograft survival.

Renal insufficiency is common in multiple myeloma and is present in almost 50% of patients at the time of diagnosis. There is a negative correlation between the presence and severity of renal disease and patient survival.

The response of the renal disease to therapy also appears to have prognostic value. The proteasomal inhibitor bortezomib has represented a significant therapeutic step forward in the treatment of multiple myeloma since its approval in 2003. Bortezomib is associated with significant improvements in response rates, complete remission rates, event-free survival, patient survival and renal recovery rates. Other chemotherapeutic agents with increasing use in patients include thalidomide and lenalidomide, presenting similar results to bortezomib.

The role for therapeutic plasma exchange (TPE) in treatment of myeloma cast nephropathy remains controversial with contrasting results from different studies, although the largest randomized controlled trial of TPE did not demonstrate any benefit. Extended daily high cut-off haemodialysis (HCO-HD) has also been shown to allow removal of large amounts of serum free light chains. Nevertheless, the studies only report reduction in free LC concentrations with HCO-HD in combination with chemotherapy. Currently, it is not known whether HCO-HD offers any additional benefit over current chemotherapeutic regimens. Randomized trials are in progress in this regard.

There are no definite treatment protocols for patients with multiple myeloma who are eligible for kidney transplantation. Kuypers et al. have reported a case in which rituximab, an anti CD20 monoclonal antibody, delayed the recurrence of LC nephropathy in the allograft kidney. Some authors believe that dose-intensive chemotherapy / high dose intensity of chemotherapy followed by stem cell transplantation could decrease disease recurrence in the allograft kidney.

The reported cases of myeloma-associated renal disorders in the transplant population are rare, with less than 50 reported. The described cases presentations were primary allograft dysfunction or renal impairment several months or years after renal transplantation. In both presentations forms, allograft survival is poor. In 2011, Goel et al. published the first recovery of graft function. The patient had an established diagnosis of primary allograft dysfunction due to allograft myeloma cast nephropathy and had been treated with plasmapheresis, chemotherapy using bortezomib and dexamethasone. Before that, Solak et al. reported a haematological remission without graft recovery in a patient with post-transplant myeloma treated with bortezomib.

The largest series, of seven patients with multiple myeloma after undergoing kidney transplantation, was recently published. The authors showed that there is significant renal involvement in these patients and patient and renal allograft survival were not worse than those of the general population with multiple myeloma and kidney transplantation, respectively. However, the authors call attention to the fact that these results should be interpreted with caution because of the small sample size and that those patients who receive kidney transplantation are highly selected, which probably introduces bias.

Our case illustrates the rare occurrence of multiple myeloma IgA lambda in a renal transplant recipient. The presence of lambda LC in casts is uncommon since most published cases showed involvement of kappa LC. This is the first case of post-transplant de novo
multiple myeloma seen in 1180 renal transplant patients followed up at our center.

The patient has responded to the implemented treatment of triple chemotherapy with dexamethasone, melphalan and bortezomib. Despite her advanced age and prolonged graft survival, treatment response was excellent. She achieved sustained complete haematological remission and returned to her basal allograft function. There were no complications associated with chemotherapy. This case is a strong argument that bortezomib could contribute to changing these patients’ outcomes.

An elevated index of suspicion is necessary to make a timely diagnosis of this serious disease, which probably determines a better prognosis.24 Anaemia and prolonged graft survival, treatment response was excellent. She achieved sustained complete haematological remission and returned to her basal allograft function. There were no complications associated with chemotherapy. This case is a strong argument that bortezomib could contribute to changing these patients’ outcomes.

In conclusion, although there are only a few cases described in the literature of this entity, we should not forget its existence, so we promote a rapid therapeutic intervention. In the last years, advances in treatment have led to an improvement of renal and vital prognosis.

References


Correspondence to:
Isabel Mesquita
Department of Nephrology, Hospital Curry Cabral
Rua da Beneficência, nº 8
1069-166
Lisboa, Portugal
E-mail: imesquita@sapo.pt